Pharmacokinetics/pharmacodynamics of echinocandins

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 23, Issue 11, 2004, Pages 805-812

  Theuretzbacher, U ^a  

^a Center For Anti Infective Agents Vienna   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; MICAFUNGIN; TRIAZOLE DERIVATIVE;

ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; CORRELATION ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; RELIABILITY; REPRODUCIBILITY; REVIEW;

ANIMALS; ANTIFUNGAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIPOPROTEINS; PEPTIDES, CYCLIC; PROTEIN BINDING; TISSUE DISTRIBUTION;

EID: 12744273574     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-004-1228-z     Document Type: Review

References (64)

1. Rex JH, Pfaller MA (2002) Has antifungal susceptibility testing come of age? Clin Infect Dis 35:982-989
2. Rex JH, Pfaller MA, Walsh TJ, Chaturvedi V, Espinel-Ingroff A, Ghannoum MA, Gosey LL, Odds FC, Rinaldi MG, Sheehan DJ, Warnock DW (2001) Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 14:643-658
3. Bartizal C, Odds FC (2003) Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus. Antimicrob Agents Chemother 47:2100-2107
4. Bowman JC, Abruzzo GK, Anderson JW, Flattery AM, Gill CJ, Pikounis VB, Schmatz DM, Liberator PA, Douglas CM (2001) Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother 45:3474-3481
5. Kurtz MB, Heath IB, Marrinan J, Dreikorn S, Onishi J, Douglas C (1994) Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-β-D-glucan synthase. Antimicrob Agents Chemother 38:1480-1489
6. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH (2001) In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother 45:327-330
7. Moore CB, Denning DW (2002) Tolerance and fungicidality in vitro of caspofungin, micafungin and anidulafungin against Candida guilliermondii. In: Program and abstracts of the 42nd interscience conference on antimicrobial agents and chemotherapy. Abstract no. M-230
8. Espinel-Ingroff A (1998) Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 36:2950-2956
9. Pfaller MA, Marco F, Messer SA, Jones RN (1998) In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis 30:251-255
10. Stone JA, Holland SD, Wickersham PJ, Sterrett A, Schwartz M, Bonfiglio C, Hesney M, Winchell GA, Deutsch PJ, Greenberg H, Hunt TL, Waldman SA (2002) Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 46:739-745
11. Stone JA, Xu X, Winchell GA, Deutsch PJ, Pearson PG, Migoya EM, Mistry GC, Xi L, Miller A, Sandhu P, Singh R, DeLuna F, Dilzer SC, Lasseter KC (2004) Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 48:815-823
12. Balani SK, Xu X, Arison BH, Silva MV, Gries A, DeLuna FA, Cui D, Kari PH, Ly T, Hop CE, Singh R, Wallace MA, Dean DC, Lin JH, Pearson PG, Baillie TA (2000) Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab Dispos 28:1274-1278
13. Pawlitz D, Young M, Klepser M (2003) Micafungin: a new echinocandin antifungal. Formulary 38:354
14. Hiemenz J, Cagnoni P, Simpson D, Devine S, Chao N (1999) Maximum tolerated dose and pharmacokinetics of FK463 in combination with fluconazole for the prophylaxis of fungal infections in adult bone marrow or peripheral stem cell transplant patients. In: Program and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy. Abstract 1648
15. Mukai T, Ohkuma T, Nakahara K, Takaya T, Uematsu T, Azuma J (2001) Pharmacokinetics of FK463, a novel echinocandin analogue, in elderly and non-elderly subjects. In: Program and abstracts of the 41st interscience conference on antimicrobial agents and chemotherapy
16. Micafungin leaftlet (2001) 3rd version, English translation. Fujisawa, Osaka
17. U.S. Food and Drug Administration (2001) Cancidas™ (caspofungin acetate for intravenous injection), Merck Corporation, NDA 21-227. Background document for Antiviral Drug Products Advisory Committee Meeting. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3676b1_01.pdf. Cited 10 Jan 2001
18. European Agency for the Evaluation of Medicinal Products (2001) Caspofungin (MSD, Merck Sharp & Dohme Ltd). Scientific discussion, CPMP/246/01. http://www.emea.eu.int/humandocs/PDFs/EPAR/cancidas/224601en6.pdf Cited 4 Oct 2004
19. Thye D, Kilfoil T, Kilfoil G, Henkel T (2002) Anidulafungin: safety and pharmacokinetics in subjects receiving concomitant cyclosporine. In: Program and abstracts of the 42nd interscience conference on antimicrobial agents and chemotherapy. Abstract no. A-1836
20. Thye D, Marbury T, Kilfoil T, Kilfoil G, Henkel T (2002) Anidulafungin: pharmacokinetics in subjects with renal impairment. In: Program and abstracts of the 42nd interscience conference on antimicrobial agents and chemotherapy. Abstract no. A-1391
21. Rajman I, Desante K, Hatcher B, Hemingway J, Lachno R, Brooks S, Turik M (1997) LY303366 single intravenous dose pharmacokinetics and safety in healthy volunteers. In: Program and abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy. Abstract no. F-74
22. Dowell J, Pu F, Lee J, Stogniew M, Krause D, Henkel T (2003) A clinical mass balance study of anidulafungin (ANID) showing complete fecal elimination. In: Program and abstracts of the 43rd interscience conference on antimicrobial agents and chemotherapy. Abstract no. A-1576
23. De Repentigny L, Phaneuf M, Mathieu LG (1992) Gastrointestinal colonization and systemic dissemination by Candida albicans and Candida tropicalis in intact and immunocompromised mice. Infect Immun 60:4907-4914
24. Rajasingham KC, Challacombe SJ, Tovey S (1989) Ultrastructure and possible processes involved in the invasion of host epithelial cells by Candida albicans in vaginal candidosis. Cytobios 60:11-20
25. Lopes-Bezerra LM, Filler SG (2003) Interactions of Aspergillus fumigatus with endothelial cells: internalization, injury, and stimulation of tissue factor activity. Blood 10:1182
26. Cooper CR, McGinnis MR (1997) Pathology of Penicillium marneffei. An emerging acquired immunodeficiency syndrome-related pathogen. Arch Pathol Lab Med 121:798-804
27. Levitz SM, Nong SH, Seetoo KF, Harrison TS, Speizer RA, Simons ER (1999) Cryptococcus neoformans resides in an acidic phagolysosome of human macrophages. Infect Immun 67:885-890
28. Eissenberg LG, Goldman WE, Schlesinger PH (1993) Histoplasma capsulatum modulates the acidification of phagolysosomes. J Exp Med 177:1605-1611
29. Hajdu R, Thompson R, Sundelof JG, Pelak BA, Bouffard FA, Dropinski JF, Kropp H (1997) Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob Agents Chemother 41:2339-2344
30. Martin E, Stuben A, Gorz A, Weller U, Bhakdi S (1994) Novel aspect of amphotericin B action: accumulation in human monocytes potentiates killing of phagocytosed Candida albicans. Antimicrob Agents Chemother 38:13-22
31. Pascual A, Garcia I, Conejo C, Perea EJ (1993) Uptake and intracellular activity of fluconazole in human polymorphonuclear leukocytes. Antimicrob Agents Chemother 37:187-190
32. Perfect JR, Savani DV, Durack DT (1993) Uptake of itraconazole by alveolar macrophages. Antimicrob Agents Chemother 37:903-904
33. Craig WA, Suh B (1991) Protein binding and the antimicrobial effects: methods for the determination of protein binding. In: Lorian V (ed) Antibiotics in laboratory medicine. Williams & Wilkins, Baltimore, pp 367-402
34. Ping L, Miller M, Derendorf H (2002) Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. Int J Antimicrob Agents 19:285-290
35. Andes D, Craig WA (2002) Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 19:261-268
36. Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ (2002) Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother 46:834-840
37. Hajdu R, Thompson R, Sundelof JG, Pelak BA, Bouffard FA, Dropinski JF, Kropp H (1997) Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob Agents Chemother 41:2339-2344
38. Petraitiene R, Petraitis V, Groll AH, Candelario M, Sein T, Bell A, Lyman CA, McMillian CL, Bacher J, Walsh TJ (1999) Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrob Agents Chemother 43:2148-2155
39. Zhanel GG, Saunders DG, Hoban DJ, Karlowsky JA (2001) Influence of human serum on antifungal pharmacodynamics with Candida albicans. Antimicrob Agents Chemother 45:2018-2022
40. Andes D, Marchillo K, Conklin R, Krishna G, Ezzet F, Cacciapuoti A, Loebenberg D (2004) Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother 48:137-142
41. Bartizal K, Gill CJ, Abruzzo GK, Flattery AM, Kong L, Scott PM, Smith JG, Leighton CE, Bouffard A, Dropinski JF, Balkovec J (1997) In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 41:2326-2332
42. Ernst EJ, Roling EE, Petzold CR, Keele DJ, Klepser ME (2002) In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob Agents Chemother 46:3846-3853
43. Tawara S, Ikeda F, Maki K, Morishita Y, Otomo K, Teratani N, Goto T, Tomishima M, Oliki H, Yamada A, Kawabata K, Takasugi H, Sakane K, Tanaka H, Matsumoto F, Kuwahara S (2000) In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 44:57-62
44. Schafer-Korting M, Korting HC, Rittler W, Obermuller W (1995) Influence of serum protein binding on the in vitro activity of antifungal agents. Infection 23:292-297
45. Groll AH, Walsh TJ (2001) Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin Investig Drugs 10:1545-1558
46. Petraitiene R, Petraitis V, Groll AH, Sein T, Schaufele RL, Francesconi A, Bacher J, Avila NA, Walsh T (2002) Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 46:12-23
47. Petraitis V, Petraitiene R, Groll AH, Roussillon K, Hemmings M, Lyman CA, Sein T, Bacher J, Bekersky I, Walsh TJ (2002) Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 46:1857-1869
48. Bowman JC, Hicks PS, Kurtz MB, Rosen H, Schmatz DM, Liberator PA, Douglas CM (2002) The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 46:3001-3012
49. Ernst EJ, Klepser ME, Pfaller MA (2000) Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother 44:1108-1111
50. Graybill JR (1994) Is there a correlation between serum antifungal drug concentration and clinical outcome? J Infect 28(Suppl 1):17-24
51. Andes D (2003) Clinical pharmacodynamics of antifungals. Infect Dis Clin North Am 17:635-649
52. Burgess DS, Hastings RW, Summers KK, Hardin TC, Rinaldi MG (2000) Pharmacodynamics of fluconazole, itraconazole, and amphotericin B against Candida albicans. Diagn Microbiol Infect Dis 36:13-18
53. Rex JH, Pfaller MA, Walsh TJ, Chaturvedi V, Espinel-Ingroff A, Ghannoum MA, Gosey LL, Odds FC, Rinaldi MG, Sheehan DJ, Warnock DW (2001) Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 14:643-658
54. Andes D, Marchillo K, Stamstad T, Conklin R (2003) In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model. Antimicrob Agents Chemother 47:1193-1199
55. Chiou CC, Mavrogiorgos N, Tillem E, Hector R, Walsh TJ (2001) Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus. Antimicrob Agents Chemother 45:3310-3321
56. Wiederhold NP, Kontoyiannis DP, Chi J, Prince RA (2003) In vivo pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis. In: Program and abstracts of the 43rd interscience conference on antimicrobial agents and chemotherapy. Abstract M-476
57. Nakai T, Watabe E, Otomo K, Hatano K, Ikeda F (2002) In vitro pharmacodynamic characterization of micafungin against 5 different Candida species. In: Program and abstracts of the 42nd interscience conference on antimicrobial agents and chemotherapy. Abstract no. A-494
58. Pettengell K, Mynhardt J, Kluyts T, Soni P (1999) A multicenter study to determine the minimal effective dose of FK463 for the treatment of esophageal candidiasis in HIV-positive patients. In: Program and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy. Abstract no. 1421
59. Petraitis V, Petraitiene R, Groll AH, Sein T, Schaufele RL, Lyman CA, Francesconi A, Bacher J, Piscitelli SC, Walsh TJ (2001) Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother 45:471-479
60. Groll AH, Mickiene D, Petraitiene R, Petraitis V, Lyman CA, Bacher JS, Piscitelli SC, Walsh TJ (2001) Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother 45:2845-2855
61. Andes D, Marchillo K, Lowther J, Bryskier A, Stamstad T, Conklin R (2003) In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob Agents Chemother 47:1187-1192
62. Denning DW (2002) Echinocandins: a new class of antifungal. J Antimicrob Chemother 49:889-891
63. Klepser ME, Malone D, Lewis RE, Ernst EJ, Pfaller MA (2000) Evaluation of voriconazole pharmacodynamics using time-kill methodology. Antimicrob Agents Chemother 44:1917-1920
64. Ernst EJ, Yodoi K, Roling EE, Klepser ME (2002) Rates and extents of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against Candida lusitaniae determined by microdilution, E test, and time-kill methods. Antimicrob Agents Chemother 46:578-581